Company: BioMarin Pharmaceuticals ( BMRN)

Drug/indication: Peg-Pal for phenylketonuria (PKU)

Estimated timing: Third quarter

Recent stock performance: At $19, the stock is flat for the year, off its recent high of $25 reached in May.

Peg-Pal is a follow-on therapy for PKU that is being developed as a treatment for patients who do not respond to Biomarin's currently marketed PKU drug Kuvan. This phase II study treats 35 patients with PKU for 16 weeks.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)